Hydroxyurea maintains working memory function in pediatric sickle cell disease

PLoS One. 2024 Jun 27;19(6):e0296196. doi: 10.1371/journal.pone.0296196. eCollection 2024.

Abstract

Sickle cell disease (SCD) decreases the oxygen-carrying capacity of red blood cells. Children with SCD have reduced/restricted cerebral blood flow, resulting in neurocognitive deficits. Hydroxyurea is the standard treatment for SCD; however, whether hydroxyurea influences such effects is unclear. A key area of SCD-associated neurocognitive impairment is working memory, which is implicated in other cognitive and academic skills. The neural correlates of working memory can be tested using n-back tasks. We analyzed functional magnetic resonance imaging (fMRI) data of patients with SCD (20 hydroxyurea-treated patients and 11 controls, aged 7-18 years) while they performed n-back tasks. Blood-oxygenation level-dependent (BOLD) signals were assessed during working memory processing at 2 time points: before hydroxyurea treatment and ~1 year after treatment was initiated. Neurocognitive measures were also assessed at both time points. Our results suggested that working memory was stable in the treated group. We observed a treatment-by-time interaction in the right cuneus and angular gyrus for the 2- >0-back contrast. Searchlight-pattern classification of the 2 time points of the 2-back tasks identified greater changes in the pattern and magnitude of BOLD signals, especially in the posterior regions of the brain, in the control group than in the treated group. In the control group at 1-year follow-up, 2-back BOLD signals increased across time points in several clusters (e.g., right inferior temporal lobe, right angular gyrus). We hypothesize that these changes resulted from increased cognitive effort during working memory processing in the absence of hydroxyurea. In the treated group, 0- to 2-back BOLD signals in the right angular gyrus and left cuneus increased continuously with increasing working memory load, potentially related to a broader dynamic range in response to task difficulty and cognitive effort. These findings suggest that hydroxyurea treatment helps maintain working memory function in SCD.

MeSH terms

  • Adolescent
  • Anemia, Sickle Cell* / drug therapy
  • Anemia, Sickle Cell* / physiopathology
  • Antisickling Agents / pharmacology
  • Antisickling Agents / therapeutic use
  • Brain / diagnostic imaging
  • Brain / drug effects
  • Brain / physiopathology
  • Case-Control Studies
  • Child
  • Female
  • Humans
  • Hydroxyurea* / pharmacology
  • Hydroxyurea* / therapeutic use
  • Magnetic Resonance Imaging*
  • Male
  • Memory, Short-Term* / drug effects

Substances

  • Hydroxyurea
  • Antisickling Agents